3-[2-(2-butoxyethoxy)ethoxy]-1-propaneamine | 84267-53-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-[2-(2-butoxyethoxy)ethoxy]-1-propaneamine
• 英文别名: 3-[2-(2-Butoxyethoxy)ethoxy]propan-1-amine
• CAS: 84267-53-8
• 化学式: C₁₁H₂₅NO₃
• 分子量: 219.324
• InChiKey: MVAHEOXEQJMGRW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  15
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  53.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-[2-(2-butoxyethoxy)ethoxy]-1-propaneamine 在 吡啶 、 三乙胺 作用下， 以 水 为溶剂， 反应 19.0h， 生成
  参考文献：
  名称：

  掺杂分子半导体：液晶per二酰亚胺的n型掺杂。

  摘要：

  DOI：

  10.1021/ja016410k
• 作为产物：
  描述：

  3-[2-(2-butoxyethoxy)ethoxy]propanenitrile 在 platinum(IV) oxide 、 氢气 作用下， 以 乙醇 、 氯仿 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 42.0h， 以94%的产率得到3-[2-(2-butoxyethoxy)ethoxy]-1-propaneamine
  参考文献：
  名称：

  掺杂分子半导体：液晶per二酰亚胺的n型掺杂。

  摘要：

  DOI：

  10.1021/ja016410k

文献信息

• METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20160176916A1

  公开（公告）日：2016-06-23

  The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.

  本申请提供了作为蛋白质降解诱导基团的双功能化合物。本申请还涉及通过使用将结合脑白质蛋白的基团与能够结合到靶向蛋白的配体相连的双功能化合物来实现内源蛋白的靶向降解的方法，该方法可用于治疗增殖性疾病。本申请还提供了制备本申请化合物及其中间体的方法。
• COMPOSITIONS IN THE FORM OF AN INJECTALE AQUEOUS SOLUTION COMPRISING HUMAN GLUCAGON AND A CO-POLYAMINO ACID
  申请人：ADOCIA

  公开号：US20190275110A1

  公开（公告）日：2019-09-12

  Physically stable compositions in the form of an injectable aqueous solution, the pH of which is comprised from 6.0 to 8.0, having at least: human glucagon and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, in one embodiment, the compositions according to the invention further includes a gastrointestinal hormone.

  物理上稳定的组合物以可注射的水溶液形式存在，其pH值为6.0至8.0，至少包括：人胰高血糖素和带有羧基电荷和疏水基团Hy的共聚氨基酸，在一种实施方式中，根据本发明的组合物进一步包括肠道激素。
• CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION
  申请人：Manoharan Muthiah

  公开号：US20120035115A1

  公开（公告）日：2012-02-09

  The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.

  该发明涉及公式I或II的化合物：在一种实施方式中，该发明涉及化合物和用于将配体与寡核苷酸结合的过程。该发明进一步涉及治疗各种疾病和疾病的方法，例如病毒感染、细菌感染、寄生虫感染、癌症、过敏、自身免疫疾病、免疫缺陷和免疫抑制。
• COMPOUNDS FOR TARGETING ENDOTHELIAL CELLS, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR THEIR USE
  申请人：Von Wronski Mathew A.

  公开号：US20110262366A1

  公开（公告）日：2011-10-27

  The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy.

  本发明提供了用于靶向内皮细胞、肿瘤细胞或其他表达NP-1受体的细胞的化合物，包含这些化合物的组合物以及它们的使用方法。此外，本发明还包括用于可视化、治疗或放射治疗的诊断、治疗和放射治疗组合物。
• Folate Conjugates
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20140045919A1

  公开（公告）日：2014-02-13

  The present invention provides iRNA agent including at least one monomer having the structure shown in formula (I′) wherein: A and B are each independently for each occurrence O, N(R N ) or S; X is H, a protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a polymer, —P(Z′)(Z″)O-L 6 -Q′-L 7 -OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, or an oligonucleotide; Y is H, a protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-L 6 -Q′-L 7 -OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, or an oligonucleotide; R is folate, a folate analog a folate mimic or a folate receptor binding ligand; L 6 and L 7 are each independently for each occurrence —(CH 2 ) n —, —C(R′)(R″)(CH 2 ) n —, —(CH 2 ) n C(R′)(R″)—, —(CH 2 CH 2 O) m CH 2 CH 2 —, or —(CH 2 CH 2 O) m CH 2 CH 2 NH—; Q′ is NH, O, S, CH 2 , C(O)O, C(O)NH, —NH—CH(R a )—C(O)—, —C(O)—CH(R a )—NH—, CO, where R a is H or amino acid side; chain. R′ and R″ are each independently H, CH 3 , OH, SH, NH 2 , NH(Alkyl=Me, Et, Pr, isoPr, Bu, Bn) or N(diAlkyl=Me 2 , Et 2 , Bn 2 ); Z′, Z″, Z′″ and Z″″ are independently O or S; n represent independently for each occurrence 1-20; and m represent independently for each occurrence 0-50.

  本发明提供了包含至少一个单体的iRNA剂，该单体的结构如公式（I'）所示：其中：A和B分别独立于每个出现的O，N（RN）或S；X为H，保护基，磷酸基，磷酸二酯基，活化磷酸基，活化亚磷酸基，磷酰胺酯，固体支持，-P（Z'）（Z"）O-核苷，-P（Z'）（Z"）O-寡核苷酸，脂质，PEG，类固醇，聚合物，-P（Z'）（Z"）O-L6-Q'-L7-OP（Z'"）（Z"）O-寡核苷酸，核苷酸或寡核苷酸；Y为H，保护基，磷酸基，磷酸二酯基，活化磷酸基，活化亚磷酸基，磷酰胺酯，固体支持，-P（Z'）（Z"）O-核苷，-P（Z'）（Z"）O-寡核苷酸，脂质，PEG，类固醇，亲脂性物质，聚合物，-P（Z'）（Z"）O-L6-Q'-L7-OP（Z'"）（Z"）O-寡核苷酸，核苷酸或寡核苷酸；R为叶酸，叶酸类似物，叶酸模拟物或叶酸受体结合配体；L6和L7分别独立于每个出现的-(CH2)n-，-C（R'）（R"）（CH2)n-，-（CH2）nC（R'）（R"）-，-（CH2CH2O）mCH2CH2-或-（CH2CH2O）mCH2CH2NH-；Q'为NH，O，S，CH2，C（O）O，C（O）NH，-NH-CH（Ra）-C（O）-，-C（O）-CH（Ra）-NH-，CO，其中Ra为H或氨基酸侧链；R'和R"分别独立于H，CH3，OH，SH，NH2，NH（Alkyl=Me，Et，Pr，isoPr，Bu，Bn）或N（diAlkyl=Me2，Et2，Bn2）；Z'，Z"，Z'"和Z""分别独立于O或S；n表示独立于每个出现的1-20；m表示独立于每个出现的0-50。